COVID-19 Treatment at AFC Urgent Care Sugar Land

APPOINTMENTS ARE REQUIRED

AFC Urgent Care Sugar Land is now offering COVID-19 treatment options for COVID positive patients at our Sugar Land location only, by appointment.

We are now offering oral therapeutic treatment options- Molnupravir and Paxlovid. It is recommended that you start covid treatment as soon as possible once you test positive for the virus. Please check in online to determine your eligibility and arrange your telemedicine COVID therapy consultation. Candidates who have active infections and are at a higher risk of complications will be considered for eligibility.

Our goal is to provide you with the resources and information you need to better care for yourself and your family.

Molnupravir

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Merck’s molnupiravir for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate. Molnupiravir is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Molnupiravir is not authorized for use in patients younger than 18 years of age because molnupiravir may affect bone and cartilage growth. It is not authorized for the pre-exposure or post-exposure prevention of COVID-19 or for initiation of treatment in patients hospitalized due to COVID-19 because benefit of treatment has not been observed in people when treatment started after hospitalization due to COVID-19.

Molnupiravir is a medication that works by introducing errors into the SARS-CoV-2 virus’ genetic code, which prevents the virus from further replicating. Molnupiravir is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules. Molnupiravir is not authorized for use for longer than five consecutive days. (FDA, Dec 2022).

Paxlovid

The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset.

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations. Paxlovid is administered as three tablets (two tablets of nirmatrelvir and one tablet of ritonavir) taken together orally twice daily for five days, for a total of 30 tablets. Paxlovid is not authorized for use for longer than five consecutive days. (FDA, Dec 2022).

COVID-19 treatment is available at our Sugar Land locations every day from 8 am to 8 pm. Schedule your appointment today. For any addtional questions or concerns please contact us at (281) 277-0036

Protect Yourself. Protect Others.

• Wear a mask.
• Cover your nose and mouth.
• Wash your hands: Use soap and water for 20 seconds. Or apply a hand sanitizer that contains 60% alcohol.
• Keep your distance.
• Keep two arm-lengths or 6 feet apart. Avoid crowds.
• Get a flu shot
• Get tested.
• Get vaccinated
• Travel informed